Search Within

Dean Bajorin

Formats
  1. Journal Article (346)
  2. Meeting Abstract (283)
  3. Book Section (17)
  4. Correspondence (6)
  5. Conference Paper (5)
  6. Review (3)
  7. Book Whole (1)
  8. Editorial (1)
  9. Research Letter (1)
Groups
  1. Department of Medicine (663)
  2. Genitourinary Oncology Service (663)
  3. Solid Tumor Oncology Division (663)
  4. Surgery (283)
  5. Urology (273)
  6. Survivorship Research (233)

More Groups

People
  1. Jonathan Rosenberg (205)
  2. Gopakumar Iyer (164)
  3. Hikmat Al-Ahmadie (150)
  4. George Bosl (147)
  5. Bernard Bochner (141)
  6. David Solit (130)

More People

Years
  1. 2025 (12)
  2. 2024 (15)
  3. 2023 (17)
  4. 2022 (29)
  5. 2021 (32)
  6. 2020 (36)

More Years

Publications
  1. Journal of Clinical Oncology (270)
  2. Annals of Oncology (27)
  3. Cancer (26)
  4. Journal of Urology (25)
  5. Modern Pathology (19)
  6. Laboratory Investigation (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (280)
  2. Elsevier Science, Inc. (59)
  3. Elsevier Inc. (51)
  4. American Association for Cancer Research (40)
  5. Wiley Blackwell (40)
  6. Oxford University Press (35)

More Publishers

Results (663)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • DNA damage repair (DDR) germline mutations in patients (Pts) with urothelial carcinoma (UC)
    Meeting Abstract

    Carlo, M. I.; Vijai, J.; Mandelker, D.; Kemel, Y.; Regazzi, A. M.; Zhang, L.; Stadler, Z. K.; Walsh, M. F.; Cadoo, K. A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Estimation of tumor-derived mutant allele fractions in cfDNA by shallow whole genome sequencing and fragment size analysis
    Meeting Abstract

    Yang, J.; Marass, F.; Ulz, P.; Shady, M.; Cheng, M. L.; Kothari, P.; Gedvilaite, E.; Somnay, S.; Shukla, N.; Modak, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • A new twist to an old tale: Immunotherapy in non-muscle-invasive bladder cancer
    Journal Article

    Funt, S. A.; Pietzak, E. J.; Bajorin, D. F.
    European Urology Oncology (2018)

    Fulltext@MSK | Save
  • Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis
    Meeting Abstract

    Bolton, K.; Ptashkin, R.; Braunstein, L.; Kelly, D.; Devlin, S. M.; Coombs, C. C.; Moarii, M.; Patel, M.; Bernard, E.; Berthon, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045
    Meeting Abstract

    Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D.; Choueiri, T. K.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-GuĂ©rin (BCG): Phase II KEYNOTE-057 trial
    Meeting Abstract

    de Wit, R.; Kulkarni, G. S.; Uchio, E.; Singer, E. A.; Krieger, L.; Grivas, P.; Bajorin, D.; Seo, H. K.; Mourey, L.; Kamat, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)
    Meeting Abstract

    Rosenberg, J. E.; Bajorin, D. F.; Smith, A.; D'Cruz, C.; Lanasa, M.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
    Journal Article

    Leiserson, M. D. M.; Syrgkanis, V.; Gilson, A.; Dudik, M.; Gillett, S.; Chayes, J.; Borgs, C.; Bajorin, D. F.; Rosenberg, J. E.; Funt, S.; more...
    PLoS ONE (2018)

    Fulltext@MSK | Save
  • Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC)
    Meeting Abstract

    Teo, M. Y.; Al-Ahmadie, H.; Seier, K.; Ostrovnaya, I.; Regazzi, A. M.; Dalbagni, G.; Bochner, B. H.; Funt, S.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save